Praktické lékárenství – 2/2019

www.praktickelekarenstvi.cz e38 AKTUÁLNÍ FARMAKOTERAPIE HYPNOTIKA V LÉČBĚ NESPAVOSTI PRAKTICKÉ LÉKÁRENSTVÍ PostedApprovedLabeling-Text.pdf 18. Krystal AD, Huang H, Zummo J, et al. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg. Sleep Med 2012; 13: 691–696. 19. Rozerem (ramelteon tablets) prescribing information. Deerfield, Illinois: Takeda Pharma- ceuticals America Inc.; 2010. Dostupné na: http://general.takedapharm.com/content/file. aspx?filetypecode=rozerempi & cacheRandomizer=15ac1dc2-362c-4f72-b98a-5a334d7a2545 20. Almeida Montes LG, Ontiveros Uribe MP, Cortés Sotres J, et al. Treatment of primary in- somnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci 2003; 28: 191–196. 21. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007; 30: 1555–1561. 22. Silenor (doxepin tablets) prescribing information. Morristown, New Jersey: Pernix Thera- peutics; 2010. Dostupné na: https://www.silenor.com/Content/pdf/prescribing-information. pdf 23. Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev 2015; 19: 75–83. 24. Food and Drug Administration FDA approves new type of sleep drug, Belsomra. Dostupné na: http://www.fda.gov/newsevents/newsroom/pressannouncements/ ucm409950.htm 25. Belsomra (suvorexant tablets) prescribing information. White-house Station, New Jer- sey: Merck & Co., Inc. Dostupné na: https://www.merck.com/product/usa/pi_circulars/b/ belsomra/belsomra_pi.pdf